Shigella Vaccine Candidate

About Valneva

Valneva is a specialty vaccine company with a mission to address unmet medical needs in infectious disease prevention. It has successfully commercialized three vaccines, including the world's first single-shot chikungunya vaccine, and is advancing a late-stage pipeline highlighted by a Lyme disease vaccine candidate developed with Pfizer. The company's strategy is built on an integrated business model, a focus on niche or neglected diseases, and strategic partnerships to maximize the value of its assets.

About Valneva SE

Valneva SE is a fully integrated specialty vaccine company with a mission to address unmet medical needs in infectious diseases through prophylactic vaccines. Its strategy combines proprietary technology platforms, including the EB66® cell line, with an end-to-end business model to control development, manufacturing, and commercialization. Key achievements include the launch of the world's only licensed chikungunya vaccine, a commercial portfolio for travel health, and a robust late-stage pipeline featuring a promising Lyme disease vaccine candidate in partnership with Pfizer.

Therapeutic Areas

Other Shigellosis Drugs